ORIGINAL RESEARCH article

Front. Cardiovasc. Med.

Sec. Cardiovascular Biologics and Regenerative Medicine

Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1517320

Directing Cell Delivery to Murine Atherosclerotic Aortic Lesions via Targeting Inflamed Circulatory Interface using Nanocarriers

Provisionally accepted
Carlos Theodore HuertaCarlos Theodore Huerta1Leiming ZhangLeiming Zhang1Yulexi Y OrtizYulexi Y Ortiz1Yan LiYan Li1Elnaz ZeynalooElnaz Zeynaloo2Emre DikiciEmre Dikici2,3Teruna J SiahaanTeruna J Siahaan4Sapna K DeoSapna K Deo2,3Sylvia DaunertSylvia Daunert2,3Zhao-Jun LiuZhao-Jun Liu1,5*Omaida C VelazquezOmaida C Velazquez1,5
  • 1DeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, United States
  • 2Department of Biochemistry and Molecular Biology, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, United States
  • 3Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute, College of Engineering, University of Miami, Miami, Florida, United States
  • 4Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, Kansas, United States
  • 5Division of Vascular and Endovascular Surgery, DeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, United States

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

CTH, YYO, YL, LZ, and MMR have no commercial or financial relationships that could be construed as a potential conflict of interest. SKD, SD, ZJL, OCV are inventors for IP (US NPA 16/567,731), which is licensed by University of Miami. ZJL and OCV declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: the E-selectin gene modification technologies described in referenced articles by ZJL and OCV were developed in our research laboratory and patented/licensed by the University of Miami. This technology is currently under pre-clinical development by Ambulero Inc., a new start-up company out of the University of Miami that focuses on developing new vascular treatments for ischemic conditions. ZJL and OCV, serve as consultants and scientific and medical advisory officers in Ambulero Inc.

Keywords: Stem Cell Therapy, cell-based therapy, Atherosclerosis, Targeted cell delivery, ICAM-1/LFA-1, nanocarriers

Received: 30 Oct 2024; Accepted: 21 May 2025.

Copyright: © 2025 Huerta, Zhang, Ortiz, Li, Zeynaloo, Dikici, Siahaan, Deo, Daunert, Liu and Velazquez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Zhao-Jun Liu, DeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material